These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 18627322)
1. Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Derdemezis C; Filippatos T; Tselepis A; Mikhailidis D; Elisaf M Expert Opin Pharmacother; 2008 Aug; 9(11):1829-37. PubMed ID: 18627322 [TBL] [Abstract][Full Text] [Related]
2. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial. Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H; J Am Coll Cardiol; 2015 Aug; 66(5):495-507. PubMed ID: 26227186 [TBL] [Abstract][Full Text] [Related]
3. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E; Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231 [TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of additional treatment with ezetimibe in patients with coronary artery disease on statin therapy. - From the viewpoint of cholesterol metabolism.-. Okada K; Kimura K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S Circ J; 2011; 75(10):2496-504. PubMed ID: 21817821 [TBL] [Abstract][Full Text] [Related]
5. Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. Barbosa SP; Lins LC; Fonseca FA; Matos LN; Aguirre AC; Bianco HT; Amaral JB; França CN; Santana JM; Izar MC Life Sci; 2013 May; 92(14-16):845-51. PubMed ID: 23507424 [TBL] [Abstract][Full Text] [Related]
6. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. Kumar SS; Lahey KA; Day A; LaHaye SA Lipids Health Dis; 2009 Dec; 8():56. PubMed ID: 20017910 [TBL] [Abstract][Full Text] [Related]
8. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease. Okada K; Iwahashi N; Endo T; Himeno H; Fukui K; Kobayashi S; Shimizu M; Iwasawa Y; Morita Y; Wada A; Shigemasa T; Mochida Y; Shimizu T; Sawada R; Uchino K; Umemura S; Kimura K Atherosclerosis; 2012 Oct; 224(2):454-6. PubMed ID: 22892323 [TBL] [Abstract][Full Text] [Related]
9. Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia. Padhy BM; Yadav R; Gupta YK Singapore Med J; 2013 Feb; 54(2):90-5. PubMed ID: 23462833 [TBL] [Abstract][Full Text] [Related]
10. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879 [TBL] [Abstract][Full Text] [Related]
11. Effect of ezetimibe/atorvastatin combination on oxidized low density lipoprotein cholesterol in patients with coronary artery disease or coronary artery disease equivalent. Azar RR; Badaoui G; Sarkis A; Azar M; Aydanian H; Harb S; Achkouty G; Kassab R Am J Cardiol; 2010 Jul; 106(2):193-7. PubMed ID: 20599002 [TBL] [Abstract][Full Text] [Related]
12. Effects of ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial. Lee JH; Kang HJ; Kim HS; Sohn DW; Oh BH; Park YB Am J Cardiovasc Drugs; 2013 Oct; 13(5):343-51. PubMed ID: 23728830 [TBL] [Abstract][Full Text] [Related]
13. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. Goldberg RB; Guyton JR; Mazzone T; Weinstock RS; Polis A; Edwards P; Tomassini JE; Tershakovec AM Mayo Clin Proc; 2006 Dec; 81(12):1579-88. PubMed ID: 17165637 [TBL] [Abstract][Full Text] [Related]
14. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R; JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642 [TBL] [Abstract][Full Text] [Related]
15. Effect of atorvastatin and ezetimibe treatment on serum lipid profile and oxidative state in rats fed with a high-cholesterol diet. Yasim A; Ozbag D; Kilinc M; Ciralik H; Toru H; Gümüşalan Y Am J Med Sci; 2010 May; 339(5):448-52. PubMed ID: 20224310 [TBL] [Abstract][Full Text] [Related]
16. Age, abdominal obesity, and baseline high-sensitivity C-reactive protein are associated with low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B responses to ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome. Robinson JG; Ballantyne CM; Hsueh WA; Rosen JB; Lin J; Shah AK; Tomassini JE; Lowe RS; Tershakovec AM J Clin Lipidol; 2013; 7(4):292-303. PubMed ID: 23890516 [TBL] [Abstract][Full Text] [Related]
17. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. Uemura Y; Watarai M; Ishii H; Koyasu M; Takemoto K; Yoshikawa D; Shibata R; Matsubara T; Murohara T J Cardiol; 2012 Jan; 59(1):50-6. PubMed ID: 22100058 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of ezetimibe added to statin therapy in patients with primary dyslipidaemia not achieving the LDL-C treatment goal on statin monotherapy. González CA; Rubio-Guerra AF; Pavía A; Redding FJ; Cervantes JL; Zacarías JL; Yza R; Carranza J; Fernández P; Morales E; Robles FJ; Leyva JL; Rodríguez L Clin Drug Investig; 2007; 27(5):333-7. PubMed ID: 17451281 [TBL] [Abstract][Full Text] [Related]
19. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease. Gupta M; Szmitko PE; Tsigoulis M; Braga MF; Kajil M; Herjikaka S; Quan A; Teoh H; Verma S J Cardiovasc Pharmacol; 2010 Sep; 56(3):241-5. PubMed ID: 20505518 [TBL] [Abstract][Full Text] [Related]
20. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study). Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]